WASHINGTON —

The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to consumers for as low as $149 per month, according to two people familiar with the negotiations.

The agreements would also clear the way for Medicare to cover the drugs for certain beneficiaries — a move that could broaden the market for medications like Wegovy, Zepbound and Mounjaro that have already proven widely popular despite their steep prices. The list price of the drugs range from roughly $1,000 to $1,350, though the price consumers pay depends on their insurance and on discounts.

President Donald Trump is expected to announce the deals as soon as Thursday, though the people familiar with the negotiations cautioned that they are not finalized a

See Full Page